Microdosing tirzepatide — using weekly doses below the SURMOUNT-1 starting dose of 2.5 mg — has become a common off-label pattern among research-chemical users seeking better GI tolerability, cost extension, or a maintenance-style regimen after reaching goal weight. There is no FDA definition of "microdosing" tirzepatide, no Phase 3 trial has tested it, and the published Phase 3 titration starts at 2.5 mg for a reason. This article documents what a representative microdose chart looks like, how it maps onto a standard 10 mg vial reconstituted with 2 mL of bacteriostatic water, and the honest limits of what the current evidence base supports.
Key Takeaways
- "Microdosing" has no FDA definition — it is a user-coined term for weekly tirzepatide doses below 2.5 mg.
- Standard SURMOUNT-1 titration starts at 2.5 mg and ramps every 4 weeks: 5, 7.5, 10, 12.5, and 15 mg weekly.
- A typical microdose chart might start at 1 mg and plateau at 2.5–5 mg rather than ramping to 15 mg.
- Reconstitution math matters — a 10 mg vial in 2 mL of BAC water gives 5 mg per mL (1 mg per 20 units on a U-100 insulin syringe).
- Expect proportionally smaller weight loss — there is no published trial data to tell you by how much.
- Cycling off microdoses can trigger rebound weight gain similar to stopping standard doses.
Why people microdose tirzepatide
Microdosing is driven by several overlapping motivations, none of which are supported by randomised trial data in the microdose range:
- GI tolerability — starting below 2.5 mg to blunt early nausea, vomiting, and bowel disturbance.
- Cost extension — a 10 mg vial dosed at 1 mg weekly lasts roughly ten weeks instead of four.
- Maintenance after reaching goal — stepping down from 10–15 mg to a sub-therapeutic dose to preserve weight stability with lower drug exposure.
- Non-weight-loss experimentation — insulin sensitivity, anti-inflammatory, cardiovascular — all unproven at microdose ranges.
The first two have the strongest mechanistic basis. The third is plausible but understudied. The fourth is speculation at this stage.
The published Phase 3 titration schedule
SURMOUNT-1, SURMOUNT-2, and the broader tirzepatide program used a 4-week-per-step titration from 2.5 mg to the target maintenance dose. The 2.5 mg start was deliberate — it is the sub-therapeutic initiation step that the published label recommends to blunt GI side effects before true dosing begins at 5 mg and above. Weight-loss effect is modest at 2.5 mg; the serious signal appears at 5 mg and scales through 15 mg.
Table 1 — Microdose protocol vs standard SURMOUNT titration (weeks 1–20)
| Week | Standard SURMOUNT dose | Representative microdose chart |
|---|---|---|
| Week 1 | 2.5 mg | 1 mg |
| Week 2 | 2.5 mg | 1.5 mg |
| Week 3 | 2.5 mg | 2 mg |
| Week 4 | 2.5 mg | 2 mg |
| Week 5 | 5 mg | 2.5 mg |
| Week 6 | 5 mg | 2.5 mg |
| Week 7 | 5 mg | 2.5 mg |
| Week 8 | 5 mg | 2.5 mg |
| Week 9 | 7.5 mg | 3 mg |
| Week 10 | 7.5 mg | 3 mg |
| Week 11 | 7.5 mg | 3 mg |
| Week 12 | 7.5 mg | 3 mg |
| Week 13 | 10 mg | 3.5 mg |
| Week 14 | 10 mg | 4 mg |
| Week 15 | 10 mg | 4 mg |
| Week 16 | 10 mg | 4 mg |
| Weeks 17–20 | 12.5 mg → 15 mg | 4–5 mg maintenance |
The representative chart above starts well below the 2.5 mg Phase 3 initiation dose and ceilings around 4–5 mg weekly. It is one of many patterns circulated in the research-chemical community and is included here as a reference for discussion, not an endorsement.
Reconstitution math
Research-grade tirzepatide typically ships as a lyophilised powder in 10 mg or 15 mg vials. The usual reconstitution is 2 mL of bacteriostatic water into a 10 mg vial, giving 5 mg/mL. On a U-100 insulin syringe (100 units = 1 mL), that works out to 1 mg per 20 units — a convenient round number for microdose arithmetic.
Table 2 — Syringe-unit math for a 10 mg vial reconstituted with 2 mL BAC water
| Target dose | Volume (mL) | Units on U-100 insulin syringe | Doses per 10 mg vial |
|---|---|---|---|
| 0.5 mg | 0.10 mL | 10 units | 20 |
| 1.0 mg | 0.20 mL | 20 units | 10 |
| 1.5 mg | 0.30 mL | 30 units | ~6 |
| 2.0 mg | 0.40 mL | 40 units | 5 |
| 2.5 mg | 0.50 mL | 50 units | 4 |
| 3.0 mg | 0.60 mL | 60 units | ~3 |
| 5.0 mg | 1.00 mL | 100 units | 2 |
The math assumes exact 2 mL reconstitution and that the vial contains the labelled 10 mg of active peptide. Research-chemical supply varies in mass accuracy, which is one of the inherent risks of microdosing: dosing precision depends on vial accuracy that you cannot easily verify.
What the evidence does and does not say
The evidence base for microdose tirzepatide is almost entirely absent in the peer-reviewed sense. The SURMOUNT program did not test doses below 2.5 mg. There are no published RCTs comparing a microdose protocol to a standard titration or to placebo at the sub-2.5 mg range. What is known is extrapolated from pharmacokinetics, mechanism, and limited observational report:
- Tirzepatide half-life is ~5 days — weekly dosing at any level produces steady-state exposure within 4–5 weeks.
- Satiety and gastric-emptying effects are dose-related and expected to be smaller at microdoses than at 5 mg and above.
- Weight loss at 2.5 mg in trials was modest — maintenance effect at 1–2 mg would be expected to be smaller still.
- Discontinuation of tirzepatide at any dose is associated with weight regain over the following months — microdose cycling off is likely to show the same pattern.
Risks and sanity checks
Microdosing is not benign simply because the dose is low. Specific risks that microdose protocols do not eliminate:
- Sterility of multi-week vials — once reconstituted, bacteriostatic water keeps the solution usable for roughly 28 days under refrigeration; longer and the risk of microbial growth rises.
- Dose-accuracy error — small volumes on insulin syringes can produce real percentage errors on each injection.
- Thyroid, pancreatic, gallbladder — the warnings on the Mounjaro/Zepbound label are not suspended because the dose is lower.
- Pregnancy — any tirzepatide dose during pregnancy is contraindicated.
- Interaction with other medications — slowed gastric emptying can affect oral drug absorption at any dose.
Microdose protocols circulate as community lore rather than clinical guidance. Reconstitution math, sterile technique, and dose accuracy fall entirely on the end user.
Conclusion
A microdose tirzepatide chart is a user-defined pattern of weekly doses below the 2.5 mg Phase 3 initiation step. The example schedule in this article — ramping from 1 mg to a 4–5 mg maintenance ceiling — is one of many patterns in circulation and reflects an attempt to retain some of the satiety and metabolic signal of tirzepatide at lower cost and GI burden. The reconstitution math is straightforward: a 10 mg vial in 2 mL of BAC water gives 1 mg per 20 units on a U-100 insulin syringe.
The honest limitation is that there is no published trial evidence to tell you what weight loss, side-effect profile, or long-term outcome to expect at these doses. Microdosing is off-label experimentation, and the risks of research-chemical sourcing, sterile technique, and dose accuracy all stack on top of the baseline risks of tirzepatide itself.
Frequently Asked Questions
Is microdosing tirzepatide FDA-approved?
No. The FDA-approved titration (Mounjaro, Zepbound) starts at 2.5 mg weekly. Doses below 2.5 mg are off-label.
Will I lose weight on 1 mg of tirzepatide per week?
Probably some weight, but much less than on a standard 5–15 mg maintenance dose. There is no published trial data at this dose range to quantify how much.
How do I measure 1 mg of tirzepatide on an insulin syringe?
With a 10 mg vial reconstituted in 2 mL of bacteriostatic water (5 mg/mL), 1 mg is 0.2 mL, which is 20 units on a standard U-100 insulin syringe.
How long does reconstituted tirzepatide last?
With bacteriostatic water and refrigeration, roughly 28 days is a common limit cited in the research-chemical community. Beyond that, microbial contamination risk rises.
Can I microdose tirzepatide for maintenance after weight loss?
Some users do this, but there is no published trial comparing microdose maintenance to full-dose maintenance to no drug. Discontinuation at any dose is associated with weight regain.
Does microdosing avoid the thyroid or pancreatic warnings?
No. The warnings on the tirzepatide label are not suspended at lower doses. The underlying mechanistic concerns apply regardless of dose.
Is microdosing cheaper than standard dosing?
Measured per week, yes — a 10 mg vial lasts longer at 1 mg per week than at 5 mg per week. Total cost per unit of weight loss is unknown without comparative data.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. nejm.org/doi/full/10.1056/NEJMoa2206038
- Zepbound (tirzepatide) FDA label. accessdata.fda.gov Zepbound label
- FDA drug information portal. fda.gov/drugs
- SURMOUNT trial family — ClinicalTrials.gov. clinicaltrials.gov/study/NCT04184622
- Tirzepatide publication index. pubmed.ncbi.nlm.nih.gov search: tirzepatide
Research disclaimer: This article is prepared by the Peptides Hive Research Desk and documents off-label dosing patterns for educational and research-context discussion only. Microdosing tirzepatide is not FDA-approved and is not supported by Phase 3 trial data. Nothing here is medical advice, prescribing guidance, or an endorsement of research-chemical sourcing. Discuss any dosing decisions with a qualified clinician.
